BPC-157 vs HGH (Somatropin)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

✅ Stacking Partners — These compounds are commonly used together and may have synergistic effects.
BPC-157HGH (Somatropin)
CategoryPeptidesGrowth Factors
Standard DoseResearch indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury.Research indicates 1-2 IU daily for anti-aging and general optimization. 2-4 IU daily for body composition. 4-8+ IU daily in clinical GH deficiency (physician-supervised only).
TimingAdminister on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing.Bedtime injection (mimics natural nocturnal GH surge) or morning fasted. Split dosing (AM + pre-bed) for higher doses. Always on empty stomach — carbohydrates blunt GH action.
Cycle DurationTypical cycles range from 4-12 weeks depending on the injury being addressed.Continuous use is common in anti-aging protocols. 6-12 month minimum for full benefits. Clinical GHD treatment is typically lifelong.
Evidence Levelanimal_plus_anecdotalstrong_human
A

BPC-157

Peptides

Mechanism

BPC-157 is a 15-amino acid peptide derived from human gastric juice that promotes angiogenesis via dual VEGFR2-dependent (PI3K-Akt-eNOS) and VEGF-independent (Src-Caveolin-1-eNOS) nitric oxide pathways. It upregulates growth hormone receptor expression, modulates the FAK-paxillin pathway for cell migration, and counteracts damage to the nitric oxide system. Additionally, it enhances tendon fibroblast growth, promotes reticulin and collagen formation, and accelerates wound healing by mediating the NO system's protective functions.

Standard Dosing

Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury.

Timing

Administer on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing.

Cycle Duration

Typical cycles range from 4-12 weeks depending on the injury being addressed.

Side Effects

  • Mild nausea (rare)
  • Dizziness (rare)
  • Injection site irritation
  • Headache (uncommon)

Contraindications

  • Active cancer or history of cancer (theoretical concern with angiogenesis promotion)
  • Pregnancy and breastfeeding
  • Children under 18

Best Stacking Partners

TB-500GHK-CuPentadeca Arginate (PDA)
B

HGH (Somatropin)

Growth Factors

Mechanism

Human Growth Hormone (somatropin) is a 191-amino acid single-chain polypeptide produced by anterior pituitary somatotrophs. It binds the GH receptor (GHR), activating JAK2-STAT5 signaling and MAP kinase pathways. Systemically, HGH upregulates hepatic IGF-1 production, which mediates most of its anabolic effects through IGF-1R/PI3K/Akt/mTOR-driven protein synthesis. Direct GH effects include lipolysis activation, insulin antagonism, chondrocyte/osteoblast stimulation, and enhanced collagen synthesis. Effects are divided into direct (lipolysis, insulin antagonism) and indirect (IGF-1-mediated growth and anabolism).

Standard Dosing

Research indicates 1-2 IU daily for anti-aging and general optimization. 2-4 IU daily for body composition. 4-8+ IU daily in clinical GH deficiency (physician-supervised only).

Timing

Bedtime injection (mimics natural nocturnal GH surge) or morning fasted. Split dosing (AM + pre-bed) for higher doses. Always on empty stomach — carbohydrates blunt GH action.

Cycle Duration

Continuous use is common in anti-aging protocols. 6-12 month minimum for full benefits. Clinical GHD treatment is typically lifelong.

Side Effects

  • Water retention/edema
  • Joint pain (arthralgia)
  • Carpal tunnel syndrome
  • Insulin resistance/elevated blood glucose
  • Gynecomastia
  • Numbness/tingling
  • Headache
  • Potential organ growth at high doses
  • Jaw/hand growth with chronic supraphysiological use

Contraindications

  • Active cancer or active tumors
  • Diabetic retinopathy (proliferative)
  • Acute critical illness
  • Closed epiphyses with active acromegaly features
  • Prader-Willi syndrome with severe obesity/respiratory impairment
  • Pregnancy and breastfeeding

Best Stacking Partners

CJC-1295/Ipamorelin (use one or the other — not GHS + exogenous GH)BPC-157TB-500

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →